Monday, March 10, 2014
Eleven private research-stage companies raised at
least $60 million in one or more financing rounds between 2009-13. All 11 have
a platform for generating multiple drug candidates. Notable platforms include
cancer metabolism biology, antibodies/antibody-drug conjugates (ADCs) and
RNA-based therapeutics. Four of the top six are explicitly developing
treatments for rare diseases.
The companies were in discovery or preclinical
development when they raised venture money over the 2009-13 period. Seven have
since advanced lead programs into the clinic and three are now publicly traded.
(A) Company declined to provide additional information on private financing
rounds; Source: BCIQ: BioCentury Online Intelligence